3 reasons to stick with your CSL Limited shares

CSL Limited (ASX:CSL) might top $100 before too long but that’s no reason to sell.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With CSL Limited (ASX: CSL) shares currently nudging $94 it looks like they might beat Commonwealth Bank of Australia (ASX: CBA) to the psychologically impressive mark of $100. At these hefty prices some shareholders could rightly be wondering if the stock has moved into overvalued territory.

It’s a fair question considering that according to consensus data provided by Morningstar, CSL is trading on a forecast price-to-earnings (PE) ratio for the current financial year (FY) of 24.4x and a FY 2016 PE of 22.7x.

That’s undoubtedly a premium to the market’s PE ratio for FY 2016 for the S&P/ASX 300 (Index: ^AXKO) (ASX: XKO) which stands at 17.9x, especially when one considers that the forecast growth rates of CSL and the index are 8.2% and 9% respectively in FY 2016.

Despite the premium pricing of CSL’s stock, there are multiple reasons to stick with your CSL shares. These include –

  • The board acts in the interests of shareholders and has undertaken numerous share buybacks. Currently there is a $950 million buyback underway.
  • The board also sees that excess funds are returned to shareholders through dividends. The recent interim dividend (in Australian dollar terms) rose 25% on the prior corresponding period to 74 cents per share.
  • Thanks to the recently proposed US$275 million acquisition of Novartis’ influenza vaccine business, CSL is set to become the second-largest company in the global influenza vaccine industry, with manufacturing plants in the USA, UK and Australia.

CSL sits amongst a handful of outstanding ASX-listed global healthcare stocks, which include ResMed Inc. (CHESS) (ASX: RMD) and Ramsay Health Care Limited (ASX: RHC). The durability of these businesses, coupled with their growth profiles makes each of them deserving of a premium to the market, however, as the entire market continues to move higher and possibly above the 6,000 mark in the near term, investors would be wise to be vigilant to the prospect of overvaluation.

Motley Fool contributor Tim McArthur has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »